RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNVX) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel FDA-cleared local drug-delivery device designed to address high unmet medical needs in cancer treatment. The company's website is renovorx.com.

The company's core business centers on its proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which enables targeted delivery of therapeutic agents across the arterial wall near tumor sites through intra-arterial administration. This approach is designed to bathe target tumors with chemotherapy while potentially minimizing systemic toxicities compared to conventional intravenous therapy. RenovoCath, the device enabling TAMP, received FDA 510(k) clearance and is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx operates as a commercial-stage growth company with two primary business streams. First, the company actively commercializes RenovoCath as a standalone device within its FDA-cleared fields of use. As of early 2026, twelve U.S. cancer centers were utilizing RenovoCath commercially, with an additional twenty-one centers evaluating or preparing for activation. The company generated $1.1 million in revenue from RenovoCath sales during 2025, representing its initial commercial phase following receipt of first purchase orders in December 2024. Second, the company is advancing its lead clinical product candidate, intra-arterial gemcitabine (IAG), through an ongoing Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. IAG received FDA Orphan Drug Designation for both pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon approval.

The company's intellectual property portfolio includes nine issued and five pending U.S. patents, plus ten issued and seven pending patents outside the United States, covering the TAMP therapy platform and RenovoCath device with protection extending through 2045. RenovoCath has been used in more than 700 successful procedures since receiving FDA clearance. The company identifies its initial target market for RenovoCath at approximately $400 million in peak annual U.S. sales, with expansion opportunities across additional solid tumor indications potentially creating multi-billion-dollar total addressable market potential.